<p>Insmed, Inc. (NASDAQ:INSM - 获取免费报告) 在三月份的空头头寸大幅增加。截至 3 月 31 日，空头头寸总计为 13,756,534 股，比 3 月 15 日的 10,037,946 股增加了 37.0%。该公司的约 6.6% 的股份被做空。根据平均每日交易量 2,950,831 股，目前的覆盖天数比率为 4.7 天。</p>
<h2>Insmed 股票表现</h2>
<ul>
<li>罗素再平衡：3 只准备上涨的股票</li>
</ul>
<p>周三午盘交易中，INSM 的股价下跌 6.66 美元，达到 146.74 美元。该股票交易量为 2,228,362 股，而其平均交易量为 2,501,321 股。该股票的 50 日简单移动平均线为 150.23 美元，200 日简单移动平均线为 167.46 美元。公司的市值为 316.7 亿美元，市盈率为-22.89，贝塔系数为 1.10。Insmed 的 12 个月低点为 63.81 美元，12 个月高点为 212.75 美元。公司的速动比率为 3.54，流动比率为 3.83，债务与股本比率为 0.76。</p>
<p>Insmed (NASDAQ:INSM - 获取免费报告) 最近于 2 月 19 日星期四发布了季度财报。这家生物制药公司报告该季度每股收益为 (-1.54) 美元，低于市场共识预期的 (-1.07) 美元，差额为 (-0.47) 美元。Insmed 的净利润率为-210.54%，股本回报率为-168.36%。该季度的收入为 2.6384 亿美元，而分析师预期为 2.6397 亿美元。去年同期，公司每股收益为 (-1.32) 美元。公司的收入同比增长 152.6%。平均而言，卖方分析师预计 Insmed 在当前年度的每股收益为-4.56 美元。</p>
<h2>内部交易活动</h2>
<ul>
<li>股票轮换正在进行中：以下是未来的赢家</li>
</ul>
<p>在其他消息中，首席财务官 Sara Bonstein 于 2 月 3 日星期二出售了 748 股公司的股票，交易价格为 156.34 美元，总价值为 116,942.32 美元。交易完成后，首席财务官直接持有 79,758 股公司股票，价值为 12,469,365.72 美元。这笔交易代表其持股比例减少了 0.93%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席执行官 William Lewis 于 4 月 6 日星期一出售了 10,699 股 Insmed 股票，交易价格为 163.22 美元，总价值为 1,746,290.78 美元。交易完成后，首席执行官持有 301,185 股公司股票，价值为 49,159,415.70 美元。这代表其持股比例减少了 3.43%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去一个季度中，内部人士已出售 179,777 股公司股票，价值为 28,412,777 美元。公司内部人士持有公司股票的 2.10%。</p>
<h2>对 Insmed 的对冲基金看法</h2>
<p>一些对冲基金最近增加或减少了对该股票的持仓。CIBC 私人财富集团在第三季度将其在 Insmed 的持仓增加了 42.1%。CIBC 私人财富集团现在拥有 179 股生物制药公司的股票，价值为 26,000 美元，此前在该期间购买了 53 股。CoreCap Advisors 在第四季度购买了 Insmed 的新头寸，价值约为 27,000 美元。Stone House 投资管理在第三季度获得了 Insmed 的新头寸，价值约为 29,000 美元。SBI 证券有限公司在第三季度将其在 Insmed 的持仓增加了 404.9%。SBI 证券有限公司现在拥有 207 股生物制药公司的股票，价值为 30,000 美元，此前在该期间增加了 166 股。最后，GraniteShares Advisors 在第四季度购买了 Insmed 的新股份，价值约为 30,000 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>INSM 已成为几份研究报告的主题。Raymond James Financial 在 4 月 10 日星期五发布的报告中开始覆盖 Insmed。他们对该公司的评级为 “跑赢大盘”，目标价为 200.00 美元。瑞穗证券在 3 月 25 日的研究报告中将 Insmed 的目标价从 204.00 美元上调至 206.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 1 月 12 日的研究报告中对 Insmed 设定了 205.00 美元的目标价。Stifel Nicolaus 在 3 月 24 日的报告中将 Insmed 的目标价从 205.00 美元上调至 208.00 美元，并给予该股票 “买入” 评级。最后，美国银行在 3 月 24 日的研究报告中将 Insmed 的目标价从 211.00 美元上调至 213.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了强烈买入评级，二十一位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价为 212.82 美元。</p>
<p><strong>查看我们关于 INSM 的最新研究报告</strong></p>
<h2>Insmed 公司简介</h2>
<p>(获取免费报告)</p>
<p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗，特别强调难以治疗的肺部感染。公司总部位于新泽西州布里奇沃特，专注于靶向药物递送技术和新型制剂的研发，旨在改善治疗选择有限的患者的临床结果。</p>
<p>公司的主要市场产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Insmed</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Insmed 吗？</h2>
<p>在考虑 Insmed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INSM

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

<p>Insmed, Inc.（纳斯达克代码：INSM）在三月份经历了显著的空头头寸增加，增长了 37.0%，达到 13,756,534 股。目前，其 6.6% 的股份被做空，基于平均每日交易量 2,950,831 股，覆盖天数比率为 4.7 天。该股票交易价格下跌至$146.74，市值为 316.7 亿美元。Insmed 报告的季度每股收益为（$1.54），未达到预期，收入为 2.6384 亿美元，同比增长 152.6%。注意到内部人士的卖出活动，首席财务官和首席执行官最近出售了股份</p>

<p>Insmed, Inc. (NASDAQ:INSM - Get Free Report) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 13,756,534 shares, an increase of 37.0% from the March 15th total of 10,037,946 shares. Approximately 6.6% of the shares of the company are sold short. Based on an average daily volume of 2,950,831 shares, the days-to-cover ratio is presently 4.7 days.</p>
<div class="lb-trans"><p>Insmed, Inc. (NASDAQ:INSM - 获取免费报告) 在三月份的空头头寸大幅增加。截至 3 月 31 日，空头头寸总计为 13,756,534 股，比 3 月 15 日的 10,037,946 股增加了 37.0%。该公司的约 6.6% 的股份被做空。根据平均每日交易量 2,950,831 股，目前的覆盖天数比率为 4.7 天。</p>
</div><h2>Insmed Stock Performance</h2>
<div class="lb-trans"><h2>Insmed 股票表现</h2>
</div><ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素再平衡：3 只准备上涨的股票</li>
</ul>
</div><p>Shares of INSM traded down $6.66 during midday trading on Wednesday, reaching $146.74. 2,228,362 shares of the stock were exchanged, compared to its average volume of 2,501,321. The stock's 50 day simple moving average is $150.23 and its 200 day simple moving average is $167.46. The company has a market cap of $31.67 billion, a P/E ratio of -22.89 and a beta of 1.10. Insmed has a twelve month low of $63.81 and a twelve month high of $212.75. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.</p>
<div class="lb-trans"><p>周三午盘交易中，INSM 的股价下跌 6.66 美元，达到 146.74 美元。该股票交易量为 2,228,362 股，而其平均交易量为 2,501,321 股。该股票的 50 日简单移动平均线为 150.23 美元，200 日简单移动平均线为 167.46 美元。公司的市值为 316.7 亿美元，市盈率为-22.89，贝塔系数为 1.10。Insmed 的 12 个月低点为 63.81 美元，12 个月高点为 212.75 美元。公司的速动比率为 3.54，流动比率为 3.83，债务与股本比率为 0.76。</p>
</div><p>Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same quarter last year, the company posted ($1.32) earnings per share. The company's revenue was up 152.6% on a year-over-year basis. On average, sell-side analysts expect that Insmed will post -4.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Insmed (NASDAQ:INSM - 获取免费报告) 最近于 2 月 19 日星期四发布了季度财报。这家生物制药公司报告该季度每股收益为 (-1.54) 美元，低于市场共识预期的 (-1.07) 美元，差额为 (-0.47) 美元。Insmed 的净利润率为-210.54%，股本回报率为-168.36%。该季度的收入为 2.6384 亿美元，而分析师预期为 2.6397 亿美元。去年同期，公司每股收益为 (-1.32) 美元。公司的收入同比增长 152.6%。平均而言，卖方分析师预计 Insmed 在当前年度的每股收益为-4.56 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行中：以下是未来的赢家</li>
</ul>
</div><p>In other news, CFO Sara Bonstein sold 748 shares of the firm's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the completion of the sale, the chief financial officer directly owned 79,758 shares of the company's stock, valued at $12,469,365.72. This trade represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $163.22, for a total value of $1,746,290.78. Following the transaction, the chief executive officer owned 301,185 shares of the company's stock, valued at $49,159,415.70. This represents a 3.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 179,777 shares of company stock valued at $28,412,777. Company insiders own 2.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Sara Bonstein 于 2 月 3 日星期二出售了 748 股公司的股票，交易价格为 156.34 美元，总价值为 116,942.32 美元。交易完成后，首席财务官直接持有 79,758 股公司股票，价值为 12,469,365.72 美元。这笔交易代表其持股比例减少了 0.93%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席执行官 William Lewis 于 4 月 6 日星期一出售了 10,699 股 Insmed 股票，交易价格为 163.22 美元，总价值为 1,746,290.78 美元。交易完成后，首席执行官持有 301,185 股公司股票，价值为 49,159,415.70 美元。这代表其持股比例减少了 3.43%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去一个季度中，内部人士已出售 179,777 股公司股票，价值为 28,412,777 美元。公司内部人士持有公司股票的 2.10%。</p>
</div><h2>Hedge Funds Weigh In On Insmed</h2>
<div class="lb-trans"><h2>对 Insmed 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC increased its position in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 53 shares during the period. CoreCap Advisors LLC bought a new position in Insmed in the 4th quarter valued at about $27,000. Stone House Investment Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at approximately $29,000. SBI Securities Co. Ltd. lifted its holdings in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 166 shares during the period. Finally, GraniteShares Advisors LLC bought a new stake in shares of Insmed during the 4th quarter worth approximately $30,000.</p>
<div class="lb-trans"><p>一些对冲基金最近增加或减少了对该股票的持仓。CIBC 私人财富集团在第三季度将其在 Insmed 的持仓增加了 42.1%。CIBC 私人财富集团现在拥有 179 股生物制药公司的股票，价值为 26,000 美元，此前在该期间购买了 53 股。CoreCap Advisors 在第四季度购买了 Insmed 的新头寸，价值约为 27,000 美元。Stone House 投资管理在第三季度获得了 Insmed 的新头寸，价值约为 29,000 美元。SBI 证券有限公司在第三季度将其在 Insmed 的持仓增加了 404.9%。SBI 证券有限公司现在拥有 207 股生物制药公司的股票，价值为 30,000 美元，此前在该期间增加了 166 股。最后，GraniteShares Advisors 在第四季度购买了 Insmed 的新股份，价值约为 30,000 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>INSM has been the subject of several research reports. Raymond James Financial initiated coverage on Insmed in a report on Friday, April 10th. They set an &#34;outperform&#34; rating and a $200.00 price target for the company. Mizuho increased their price objective on shares of Insmed from $204.00 to $206.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, March 25th. Truist Financial set a $205.00 target price on shares of Insmed in a research note on Monday, January 12th. Stifel Nicolaus lifted their target price on shares of Insmed from $205.00 to $208.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, March 24th. Finally, Bank of America upped their price target on shares of Insmed from $211.00 to $213.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $212.82.</p>
<div class="lb-trans"><p>INSM 已成为几份研究报告的主题。Raymond James Financial 在 4 月 10 日星期五发布的报告中开始覆盖 Insmed。他们对该公司的评级为 “跑赢大盘”，目标价为 200.00 美元。瑞穗证券在 3 月 25 日的研究报告中将 Insmed 的目标价从 204.00 美元上调至 206.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 1 月 12 日的研究报告中对 Insmed 设定了 205.00 美元的目标价。Stifel Nicolaus 在 3 月 24 日的报告中将 Insmed 的目标价从 205.00 美元上调至 208.00 美元，并给予该股票 “买入” 评级。最后，美国银行在 3 月 24 日的研究报告中将 Insmed 的目标价从 211.00 美元上调至 213.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了强烈买入评级，二十一位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价为 212.82 美元。</p>
</div><p><strong>View Our Latest Research Report on INSM</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 INSM 的最新研究报告</strong></p>
</div><h2>Insmed Company Profile</h2>
<div class="lb-trans"><h2>Insmed 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗，特别强调难以治疗的肺部感染。公司总部位于新泽西州布里奇沃特，专注于靶向药物递送技术和新型制剂的研发，旨在改善治疗选择有限的患者的临床结果。</p>
</div><p>The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.</p>
<div class="lb-trans"><p>公司的主要市场产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Insmed</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insmed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insmed 公司（NASDAQ:INSM）空头头寸更新